

LJMU Research Online

Rosser, BA, Fisher, E, Eccleston, C, Duggan, GB and Keogh, E

Psychological therapies delivered remotely for the management of chronic pain (excluding headache) in adults [protocol]

http://researchonline.ljmu.ac.uk/id/eprint/14607/

Article

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

Rosser, BA, Fisher, E, Eccleston, C, Duggan, GB and Keogh, E (2021) Psychological therapies delivered remotely for the management of chronic pain (excluding headache) in adults [protocol]. Cochrane Database of Systematic Reviews (1). ISSN 1469-493X

LJMU has developed LJMU Research Online for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@ljmu.ac.uk



Cochrane Database of Systematic Reviews

Psychological therapies delivered remotely for the management of chronic pain (excluding headache) in adults (Protocol)

chronic pain (excluding neadache) in adults (Protocol)
Rosser BA, Fisher E, Eccleston C, Duggan GB, Keogh E
Rosser BA, Fisher E, Eccleston C, Duggan GB, Keogh E. Psychological therapies delivered remotely for the management of chronic pain (excluding headache) in adults (Protocol). Cochrane Database of Systematic Reviews 2021, Issue 1. Art. No.: CD013863. DOI: 10.1002/14651858.CD013863.

www.cochranelibrary.com

i



TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
BACKGROUND	2
OBJECTIVES	3
METHODS	3
ACKNOWLEDGEMENTS	6
REFERENCES	7
APPENDICES	ç
HISTORY	ç
CONTRIBUTIONS OF AUTHORS	10
DECLARATIONS OF INTEREST	10
SOURCES OF SUPPORT	10



[Intervention Protocol]

Psychological therapies delivered remotely for the management of chronic pain (excluding headache) in adults

Benjamin A Rosser¹, Emma Fisher², Christopher Eccleston³, Geoffrey B Duggan⁴, Edmund Keogh⁵

¹Liverpool John Moores University, Liverpool, UK. ²Cochrane Pain, Palliative and Supportive Care Group, Pain Research Unit, Churchill Hospital, Oxford, UK. ³Centre for Pain Research, University of Bath, Bath, UK. ⁴Bath Centre for Pain Services, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK. ⁵Department of Psychology, University of Bath, Bath, UK

Contact address: Benjamin A Rosser, b.a.rosser@ljmu.ac.uk.

Editorial group: Cochrane Pain, Palliative and Supportive Care Group. **Publication status and date:** New, published in Issue 1, 2021.

Citation: Rosser BA, Fisher E, Eccleston C, Duggan GB, Keogh E. Psychological therapies delivered remotely for the management of chronic pain (excluding headache) in adults (Protocol). *Cochrane Database of Systematic Reviews* 2021, Issue 1. Art. No.: CD013863. DOI: 10.1002/14651858.CD013863.

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Objectives

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

To determine the efficacy and harms of remotely delivered psychological therapies compared to active control, waiting list, or treatment-as-usual for the management of chronic pain in adults.



BACKGROUND

Description of the condition

Chronic pain (defined as pain lasting three months or more) is a global public health challenge. The International Association for the Study of Pain defines pain as "an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage" (Raja 2020). The prevalence of chronic pain is estimated to be between 20% and 43% globally (Eccleston 2017; Fayaz 2016; Mansfield 2016; Tsang 2008), with annual societal costs per patient estimated at EUR 10,191 (Mayer 2019). Further, the challenge is increasing as the incidence of chronic pain rises in older age (Fayaz 2016; Tsang 2008). The most common types of chronic pain in adults include chronic back pain, fibromyalgia, neuropathic pain, and headache. Chronic pain can be categorised as the disease itself (e.g. fibromyalgia) and is defined as chronic primary pain, or can be associated with or a consequence of an underlying disease (e.g. chronic cancer-related pain; Treede 2019). The personal consequences of chronic pain may be widespread, disrupting an individual's ability to engage in everyday life and occupation, affecting social relationships, and deleteriously influencing quality of life (Dueñas 2016; Reid 2011). High levels of depression and anxiety associated with chronic pain may further complicate the emotional impact (Scott 2007). Consequently, chronic pain presents a psychological, as well as physical, challenge.

Description of the intervention

Psychological therapies can address the cognitive, behavioural, and emotional factors associated with the experience of chronic pain to support self-management and the pursuit of personally meaningful goals. These interventions contribute to improvements in mood and pain-related disability (Williams 2020), and are recognised as an important component of effective pain management treatment (Eccleston 2013; Kerns 2011). However, patients and providers report that access to 'non-pharmacological', often psychological, pain treatments is constrained by multiple barriers, including geographic and economic restrictions (Becker 2017). Consequently, provision of effective and scalable support for chronic pain remains a substantial challenge.

Technological advances provide new opportunities for treatment delivery that may overcome traditional barriers and provide support remote from clinician involvement. Technology-based delivery offers the potential to liberate healthcare expertise from its temporal, geographic, and economic restrictions through partial or complete automation of treatment. Consequently, such delivery methods may increase access to psychological therapeutic support for health conditions such as chronic pain (McGuire 2017).

Relevant technologies are multiform and multiplying. Correspondingly, recent reviews emphasise the need to evaluate technology-based delivery across multiple modalities (Heapy 2015; Slattery 2019). The encouraging support for technology-based intervention delivery for chronic pain is often tempered by the disproportionate representation of specific modalities (e.g. Internet-based interventions) within the evidence-base. However, increasing investigation of technologies such as smartphones is anticipated (McGuire 2017). Consequently, rigorous verification of intervention effectiveness must match rapidly evolving technology.

This review is concerned with any technology-based delivery of psychological therapy for chronic pain that is remote from both the physical presence of the healthcare professional (HCP) and their active involvement. We employ the term 'remote delivery' for its superior descriptive capacity to other terms (such as ehealth, telehealth, telemedicine, and digital therapeutics). Fisher and colleagues also employed 'remote delivery' in their related review within child and adolescent populations (Fisher 2019), so this enables cross-review comparison. Eligible interventions will utilise technology as the primary agent of delivering psychological therapy. Technology solely facilitating distance contact between client and clinician (such as videoconferencing) does not fulfil our definition of remote delivery because the intervention, whilst remote from the HCP's physical presence, remains dependent on their active involvement and direction. We place no restrictions on technology type.

How the intervention might work

Psychological therapies comprise multiple modalities with variable intervention targets and therapeutic processes. Existing reviews suggest that psychological therapies have beneficial effects within both adult populations (Williams 2020), and child populations (Fisher 2018). Mainstream psychological approaches supporting individuals experiencing chronic pain typically derive from cognitive and behavioural models of human experience and difficulty (Eccleston 2013; Williams 2020). Traditional cognitive behavioural interventions comprise varying content including psychoeducation, identification and modification of unhelpful patterns of thought and behaviour, and the development and application of coping strategies (Kerns 2011). Whilst content varies, these interventions share an underlying aim to target the interactive relationship between internal experience and external behaviour in order to support personally meaningful engagement with life. Whilst cognitive and behavioural therapies dominate the literature, this review is not limited to any specific therapy modality.

Remote delivery of psychological therapy divorces intervention content from face-to-face clinician delivery. Technology offers increasingly varied media to achieve this end and facilitate new ways to access psychological interventions for chronic pain (including Internet-based, smartphone applications, and virtual reality). The potential impact of delivery method should not be underestimated, particularly given the emphasis within psychological interventions on the therapeutic role of clientclinician relationships (Horvath 2011; Zilcha-Mano 2017). However, as related reviews suggest, remote delivery also offers additional features beyond those of traditional therapy, which may contribute to the impact of interventions, such as immediate 24-hour access to support (Fisher 2019), and exact treatment fidelity (Heapy 2015). Consequently, whilst the intervention content and underlying psychological frameworks may appear comparable between traditional and technology-based delivery, the delivery method has the potential to influence both message and outcome.

Why it is important to do this review

Traditional face-to-face psychological therapies for chronic pain appear useful (Williams 2020). However, access to treatment is restricted by healthcare resources, geography, and cost. Remote technology-based delivery holds the potential to overcome these traditional treatment barriers. However, therapeutic equivalence between traditional and technology-



based delivery requires substantiation. Further, communication technology provides opportunities for content and delivery that outstrip what is possible face to face, and may facilitate novel interventions (Eccleston 2018). Whilst previous reviews of Internet-based psychological interventions for chronic pain are encouraging (Bender 2011; Buhrman 2016; Eccleston 2014), evolving technologies necessitate the need to consider a broader spectrum of technologies capable of remote delivery. Concern remains that technological innovation, such as smartphone applications, is outpacing regulation and evidential support, despite repeat criticism (Lalloo 2015; Portelli 2016; Rosser 2011). Consequently, a review enabling aggregation and evaluation of remote delivery - via multiple technologies - of psychological therapy for chronic pain is warranted. Fisher 2019 provides such a review of remotely delivered psychological interventions for chronic pain in children and adolescents. Williams 2020 provides a review of face-to-face psychological interventions in adults with chronic pain. We aim to complement both reviews by conducting a review of psychological interventions delivered remote from the therapist for adults with chronic pain. This review will update and supersede our previous review focused on Internet-delivered psychological therapies (Eccleston 2014).

OBJECTIVES

To determine the efficacy and harms of remotely delivered psychological therapies compared to active control, waiting list, or treatment-as-usual for the management of chronic pain in adults.

METHODS

Criteria for considering studies for this review

Types of studies

We will include peer-reviewed randomised controlled trials (RCTs). Randomised trials are the best design to minimize bias when evaluating the effectiveness of an intervention. We will exclude equivalence studies, conference abstracts, dissertations, and non-randomised studies as a quality threshold and to support confidence in the reliability of included data. We will search databases without language or date restrictions and report ongoing trials and trials with data.

Types of participants

We will include adults (≥ 18 years of age) with chronic pain. Typically, these conditions include musculoskeletal and neuropathic pain. We will include participants experiencing chronic pain as a primary symptom of a condition or disease. For example, this includes participants experiencing diabetic neuropathy, sickle cell disease, or primary chronic pain conditions. We will exclude life-limiting conditions such as cancer and participants with headache or migraine from the review to be consistent with Williams 2020. We will include studies where only a subset of participants are eligible, if characteristics and outcomes of those participants can be extracted separately. Studies must include a minimum of 20 participants in each trial arm post-treatment to be considered for inclusion.

Types of interventions

We will include psychological therapies that have recognisable psychotherapeutic content or are based on a psychological theory. Psychological therapy delivery must be predominantly remote from the therapist. We define 'remote delivery' as the transfer of intervention content remote from both therapist location and their active guidance. We will exclude trials that involve more than 30% contact time with a clinician, either in-person or via technology-mediated communication (e.g. email, phone, teleconference, online chat).

Eligible trials using remotely delivered psychological therapies may utilise various technologies, such as the Internet or smartphone application. The intervention must include content that requires the participant to engage in one or more psychologicallyinformed therapeutic activity. We will exclude interventions that only provide education or passively consumed content (e.g. description of psychological theory rather than its application). Eligible interventions must have been developed by (or under the supervision of) a qualified psychologist and based on existing psychological theory, echoing the Cochrane Review of face-to-face delivery of psychological therapies (Williams 2020). Importantly, the intervention must be potentially scalable to reach a large number of people, rather than relying on intensive one-toone interactions such as delivering interventions via Skype or videoconferencing software. All authors will agree on the included studies.

This is a rapidly evolving field, with new technologies and delivery modes emerging. Therefore, in future updates we may need to expand our inclusion criteria to include new forms of intervention modes as technology evolves.

We will compare intervention arms to control arms. We will include active controls (e.g. education), treatment-as-usual, or waiting list controls. We will combine treatment-as-usual and waiting list controls in the analyses. As described, we will exclude equivalence trials, and therefore control groups that include a psychotherapeutic content will be excluded.

Types of outcome measures

We will compare psychological interventions to control groups at two time points: 1) immediately post-treatment; and 2) follow-up. We determined an eligible timeframe for follow-up as between three and 12 months post-treatment. We will extract outcomes that are assessed by validated measures. In the event of multiple follow-up assessments, we will extract the latter time point closest to 12 months. It may be that some studies provide a longer time point beyond 12 months, and we will extract this as a secondary follow-up time point. However, the control group must remain consistent and, therefore, comparable across these time points. Where studies include multiple measures for the same outcome, we will use the most reliable and frequently employed measure within the field.

Primary outcomes

We will extract the following primary outcomes.

- Pain intensity (continuous data: e.g. numerical rating scale, visual analogue scale). Where possible, we will extract 30% reduction in pain, 50% reduction in pain, or both, separately.
- Functional disability (e.g. Functional Disability Inventory).
- Quality of life (e.g. Short Form-36).
- · Adverse events.



Secondary outcomes

We will extract the following secondary outcomes.

- Anxiety (e.g. Hamilton Anxiety Rating Scale).
- Depression (e.g. Beck Depression Inventory).
- Intervention satisfaction (e.g. numerical rating scale).
- Intervention engagement (i.e. measurement of intervention use, technology usage, and/or activity completion).
- Attrition (from baseline to follow-up).

Search methods for identification of studies

Electronic searches

We will search the following electronic databases without date or language restriction.

- CENTRAL (Cochrane Library) current issue.
- MEDLINE (OVID) 1946 to present.
- Embase (OVID) 1974 to present.
- PsycINFO (Ebsco) 1806 to present.

We will employ a comparable search strategy across databases (see Appendix 1 for the MEDLINE strategy).

Searching other resources

We will search clinicaltrials.gov and the WHO ICTRP (apps.who.int/trialsearch/) for any ongoing trials or completed trials not yet published in a peer-reviewed journal. We will enter these into the relevant 'Characteristics of studies' section. We will search the reference lists and conduct a citation search of included trials to identify any further trials that meet our eligibility criteria.

Data collection and analysis

Selection of studies

We will divide the search results between two review author pairs (BR and EK; EF and GD). Each pair will review half of the search results. In each pair, the two review authors (e.g. BR and EK) will independently determine eligibility by screening the title and abstract of studies identified by the search. We will exclude studies that clearly do not satisfy inclusion criteria, and obtain full copies of the remaining studies. Any disagreements that cannot be resolved by discussion between the two authors doing the initial screening will be subject to arbitration by a third author (CE). Two review authors (e.g. BR and EF) will independently read the full texts of the retrieved studies to identify eligible studies. We will resolve any disagreements through discussion, or by involving a third author (CE) if necessary. All review authors will agree on all included studies. We will include a PRISMA flow chart in the full review which will show the status of identified studies (Moher 2009), as recommended in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2020c, hereafter referred to as the Cochrane Handbook).

Eligible studies will meet the following criteria.

- An RCT.
- Published in a peer-reviewed scientific journal.

- Twenty or more participants in each trial arm post-treatment, for consistency with Williams 2020. Small studies are known to produce larger effect sizes (Dechartres 2013).
- Therapy is primarily psychological in at least one trial arm.
- Psychological therapy aims to facilitate adults in managing or coping with chronic pain.
- The intervention must include content that requires the participant to engage in one or more psychologically-informed therapeutic activity.
- A qualified psychologist developed or supervised the development of the psychological component of the intervention.
- Technology is the primary delivery mechanism for the psychological therapy.
- Technology-based delivery of psychological therapy is remote from clinician contact and their active guidance.
- Participants receive the intervention in their everyday setting, rather than in a clinic or laboratory.

Data extraction and management

One author will extract data from the included studies and a second author will check these data. A third author will arbitrate any disagreements. We will extract the following data.

- Article details (e.g. authorship, title, year, study funding sources, study author declarations of interest).
- Participant characteristics (e.g. sample size, age, sex, pain condition or characteristics and duration, dropout).
- Intervention characteristics (e.g. psychological theory and content, duration, delivery mode, therapeutic activity requiring participant interaction or involvement).
- Comparison characteristics (e.g. type of comparison and content).
- Methodological characteristics (e.g. study design, randomisation method, assessment points).
- Outcomes (e.g. primary and secondary outcomes).

Where there are multiple reports of the same study, we will amalgamate into a single study summary.

Assessment of risk of bias in included studies

We will assess risk of bias using the Cochrane risk of bias (RoB) version 1 tool for randomised trials (Higgins 2011). The tool assesses bias arising from multiple domains, including selection bias, performance and detection bias, attrition bias, and reporting bias. We will categorise risk for each domain in terms of low, high, or unclear. Two authors will independently assess included articles for risk of bias. We will resolve any assessment discrepancies through discussion, or by involving a third author if necessary.

Selection bias

 Random sequence generation (checking for possible selection bias). We will assess the method used to generate the allocation sequence as: low risk of bias (any truly random process, e.g. random number table, computer random number generator); or unclear risk of bias (method used to generate sequence not clearly stated). Studies using a non-random process (e.g. odd or even date of birth, hospital or clinic record number) will not meet eligibility criteria and will not be included.



Allocation concealment (checking for possible selection bias).
 The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. We will assess the methods as: low risk of bias (e.g. telephone or central randomisation; consecutively numbered, sealed, opaque envelopes); or unclear risk of bias (method not clearly stated). Studies that do not conceal allocation (e.g. open list) will be rated as high risk of bias.

Performance and detection bias

- Blinding of participants and personnel (checking for possible performance bias). In line with other Cochrane Reviews of psychological interventions (Fisher 2018; Fisher 2019; Williams 2020), we will not assess blinding of participants and personnel as it is not possible to fully blind delivery of psychological therapies. We will consider the possible influence of performance bias in the interpretation of the findings.
- Blinding of outcome assessment (checking for possible detection bias). We will assess the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We will assess the methods as: low risk of bias (assessments are completed online or directly into a database and are not able to be influenced by an outcome assessor); unclear risk of bias (it is not clear how assessments are taken, or whether the outcome assessor knows of treatment allocation); or high risk of bias (outcome assessors are aware of treatment allocation). As outcome assessment will likely be self-report, we acknowledge the possible influence of bias arising from the difficulties of fully blinding participants when delivering psychological therapies. We will consider this potential influence in interpretation of the findings.

Attrition bias

 Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data). We will assess the methods used to deal with incomplete data as: low risk (< 10% of participants did not complete the study, or study used 'baseline observation carried forward' analysis, or both); unclear risk of bias (used 'last observation carried forward' analysis); or high risk of bias (used 'completer' analysis).

Reporting bias

Selective reporting (checking for reporting bias). We will
assess whether primary and secondary outcome measures
were pre-specified and whether these were consistent with
those reported: low risk of bias (all pre-specified outcomes
are reported in manuscript and no additional outcomes are
included); unclear risk of bias (trial registration or protocol
is not available, or trial post-registered); or high risk of bias
(pre-specified outcomes are missing from trial manuscript,
additional outcomes are included in manuscript but not listed
in pre-registered database, or primary and secondary outcomes
are changed between pre-registration and manuscript).

Measures of treatment effect

We anticipate that most authors will report continuous data on our outcomes of interest. We will extract and analyse these continuous outcome data where reported. We will employ standardised mean

differences (SMDs) with 95% confidence intervals (CIs) to evaluate treatment effects for continuous data. We will interpret SMD as small (0.2), moderate (0.5), and large (0.8), in accordance with Cohen 1988.

We do not anticipate dichotomous data as this form of pain treatment outcome data is most commonly associated with headache or migraine reduction, which are excluded from this review, and adverse events are not widely reported in psychological trials. We will employ risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous data if we encounter it.

Unit of analysis issues

We expect that studies will randomise at the individual level. We will follow *Cochrane Handbook* guidance if cluster-randomisation occurs (Higgins 2020b). The clusters will be considered as the unit of analysis, rather than participants. We will collapse arms into intervention and control groups, respectively, where a study employs multiple interventions or control arms, or both. We will split the control group equally across intervention arms to enable comparisons where notable discrepancy in underpinning psychological approach or theory prohibits meaningful amalgamation. For cross-over trials, we will include the first step comparison of treatment and control. We will not include data from the second step where the arms are crossed over to avoid carryover effects of the intervention in the first step.

Dealing with missing data

We will contact authors if outcome data are missing from published studies. We will use available statistical information from the published study to calculate the necessary data (e.g. standard deviations) where possible, in accordance with *Cochrane Handbook* guidance (Higgins 2020a), in the event that these data are not available from the authors. We will not impute missing variables in analyses where outcome data are not available or calculable. In the unlikely event that both per protocol and intention-to-treat analyses are presented in published manuscripts, we will preferentially extract intention-to-treat data.

Assessment of heterogeneity

We will interpret heterogeneity by visually inspecting forest plots alongside calculating Chi² and I². We will interpret I² with reference to *Cochrane Handbook* guidelines (Deeks 2020):

- 0% to 40%; might not be important;
- 30% to 60%; may represent moderate heterogeneity;
- 50% to 90%; may represent substantial heterogeneity;
- 75% to 100%; considerable heterogeneity.

Where heterogeneity is substantial or considerable, we will investigate, and conduct sensitivity analyses if appropriate.

Assessment of reporting biases

We will assess reporting biases as part of the risk of bias assessment in this review. We will also assess funnel plots, in accordance with *Cochrane Handbook* guidance (Page 2020), where there are at least 10 studies included in each analysis.



Data synthesis

We will analyse data using Review Manager (Review Manager 2020). We will analyse outcome data using random-effects models. Where it is not possible to combine data, we will describe the findings across studies.

We will conduct the comparisons listed below for two individual therapy types initially: cognitive behavioural therapy (CBT), and acceptance and commitment therapy (ACT). We will separate comparisons by control group type (e.g. waiting-list control; active or treatment-as-usual control). We will conduct comparisons on data immediately post-treatment and at follow-up.

- CBT versus waiting-list control (no treatment), post-treatment.
- CBT versus waiting-list control (no treatment), follow-up.
- CBT versus active control, post-treatment.
- CBT versus active control, follow-up.
- ACT versus waiting-list control (no treatment), post-treatment.
- ACT versus waiting-list control (no treatment), follow-up.
- ACT versus active control, post-treatment.
- ACT versus active control, follow-up.

We will add further comparisons as separate categories of psychological therapies are identified within included studies.

Subgroup analysis and investigation of heterogeneity

We plan to conduct subgroup analyses where at least 10 eligible studies are available, evaluating the following.

- Delivery method (e.g. computer versus smartphone application).
- Delivery automation (i.e. fully automated delivery versus some therapist interaction).

We will not conduct subgroup analyses based on pain type; this approach is consistent with Williams 2020.

Sensitivity analysis

We plan to conduct sensitivity analyses in:

- trials with more than 50 participants versus less than 50 participants per arm; and
- trials assessed as low risk of bias across all bias domains.

We will also conduct sensitivity analyses excluding trials where we identify substantial or considerable heterogeneity. We will consider other sensitivity analyses as the literature evolves, and new technologies emerge. We will only conduct sensitivity analyses when there are at least 10 eligible studies to enter into the meta-analysis in either subgroup.

Summary of findings and assessment of the certainty of the evidence

Two review authors (BR and EF) will independently rate the certainty of the body of evidence for the outcomes. We will use the GRADE system to rank the certainty of the evidence using the GRADEprofiler Guideline Development Tool software (GRADEpro GDT), and the guidelines provided in the *Cochrane*

Handbook (Chapter 14, Higgins 2020c) and GRADEpro Handbook (Schünemann 2013).

The GRADE approach uses five considerations (study limitations (risk of bias); unexplained heterogeneity and inconsistency of effect; imprecision; indirectness; and publication bias) to assess the certainty of the body of evidence for each outcome. The GRADE system uses the following criteria for assigning grade of evidence.

- High: we are very confident that the true effect lies close to that of the estimate of the effect.
- Moderate: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.
- Low: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
- Very low: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

The GRADE system considers study design as a marker of quality. Randomised controlled trials are considered to yield high certainty of evidence, but they can be downgraded for important limitations. Factors that may decrease the certainty level of a body of evidence are as follows.

- Serious or very serious study limitations (risk of bias).
- · Important or serious inconsistency of results.
- Some or major indirectness of evidence.
- · Serious or very serious imprecision.
- Probability of publication bias.

We plan to include at least four 'Summary of findings' tables to present the main findings for each therapy type (e.g. CBT, ACT) versus each control comparison (e.g. waiting list, active) in a transparent and simple tabular format. In particular, we will include key information concerning the certainty of evidence, the magnitude of effect of the interventions examined, and the sum of available data on these outcomes: pain intensity, functional disability, quality of life, and adverse events.

ACKNOWLEDGEMENTS

We would like to thank Joanne Abbott for designing the search strategy.

Cochrane Review Group funding acknowledgement: this project is funded by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Cochrane Pain, Palliative and Supportive Care Review Group (PaPaS). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

The authors would like to thank the following peer reviewers: Mia Koponen, Shahnaz Nabi, Danial Sayyad, Louise Sharpe, and Thomas PH Shelton.

We thank Iris Gordon, Information Specialist for Cochrane Eyes and Vision Review Group, for peer reviewing the search strategy.



REFERENCES

Additional references

Becker 2017

Becker WC, Dorflinger L, Edmond SN, Islam L, Heapy AA, Fraenkel L. Barriers and facilitators to use of non-pharmacological treatments in chronic pain. *BMC Family Practice* 2017;**18**(1):41. [DOI: 10.1186/s12875-017-0608-2]

Bender 2011

Bender JL, Radhakrishnan A, Diorio C, Englesakis M, Jadad AR. Can pain be managed through the Internet? A systematic review of randomized controlled trials. *Pain* 2011;**152**(8):1740-50. [DOI: 10.1016/j.pain.2011.02.012]

Buhrman 2016

Buhrman M, Gordh T, Andersson G. Internet interventions for chronic pain including headache: a systematic review. *Internet Interventions* 2016;**4**:17-34. [DOI: 10.1016/j.invent.2015.12.001]

Cohen 1988

Cohen J. Statistical Power Analysis in the Behavioral Sciences. 2nd edition. Hillsdale (NJ): Lawrence Erlbaum Associates, Inc., 1988.

Dechartres 2013

Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. *BMJ* 2013;**346**:f2304.

Deeks 2020

Deeks JJ, Higgins JP, Altman DG. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.

Dueñas 2016

Dueñas M, Ojeda B, Salazar A, Mico JA, Failde I. A review of chronic pain impact on patients, their social environment and the health care system. *Journal of Pain Research* 2016;**9**:457-67. [DOI: 10.2147/JPR.S105892]

Eccleston 2013

Eccleston C, Morley SJ, Williams AC. Psychological approaches to chronic pain management: evidence and challenges. *British Journal of Anaesthesia* 2013;**111**(1):59-63. [DOI: 10.1093/bja/aet207]

Eccleston 2017

Eccleston C, Wells C, Morlion B. European Pain Management. Oxford (UK): Oxford University Press, 2018. [ISBN: 9780198785750]

Eccleston 2018

Eccleston C, Tabor A, Keogh E. Using advanced technologies to improve access to treatment, to improve treatment, and to directly alter experience. In: Turk DC, Gatchel RJ, editors(s). Psychological Approaches to Pain Management. 3rd

edition. New York (NY): Guilford Press, 2018:289-301. [ISBN: 9781462528530]

Fayaz 2016

Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. *BMJ Open* 2016;**6**(6):e010364. [DOI: 10.1136/bmjopen-2015-010364]

Fisher 2018

Fisher E, Law E, Dudeney J, Palermo TM, Stewart G, Eccleston C. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. *Cochrane Database of Systematic Reviews* 2018, Issue 9. Art. No: CD003968. [DOI: 10.1002/14651858.CD003968.pub5]

Fisher 2019

Fisher E, Law E, Dudeney J, Eccleston C, Palermo TM. Psychological therapies (remotely delivered) for the management of chronic and recurrent pain in children and adolescents. *Cochrane Database of Systematic Reviews* 2019, Issue 4. Art. No: CD011118. [DOI: 10.1002/14651858.CD011118.pub3]

GRADEpro GDT [Computer program]

McMaster University (developed by Evidence Prime, Inc.) GRADEpro GDT. Version 14 December 2020. Hamilton (ON): McMaster University (developed by Evidence Prime, Inc.). Available at gradepro.org.

Heapy 2015

Heapy AA, Higgins DM, Cervone D, Wandner L, Fenton BT, Kerns RD. A systematic review of technology-assisted self-management interventions for chronic pain: looking across treatment modalities. *The Clinical Journal of Pain* 2015;**31**(6):470-92. [DOI: 10.1097/ajp.00000000000000185]

Higgins 2011

Higgins JP, Altman DG, Sterne JA (editors). Chapter 8: assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Higgins 2020a

Higgins JP, Li T, Deeks JJ. Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.

Higgins 2020b

Higgins JP, Eldridge S, Li T. Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.



Higgins 2020c

Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.

Horvath 2011

Horvath AO, Del Re AC, Fluckiger C, Symonds D. Alliance in individual psychotherapy. *Psychotherapy* 2011;**48**(1):9-16. [DOI: 10.1037/a0022186]

Kerns 2011

Kerns RD, Sellinger J, Goodin BR. Psychological treatment of chronic pain. *Annual Review of Clinical Psychology* 2011;**7**:411-34. [DOI: 10.1146/annurev-clinpsy-090310-120430]

Lalloo 2015

Lalloo C, Jibb LA, Rivera J, Agarwal A, Stinson JN. "There's a pain app for that": review of patient-targeted smartphone applications for pain management. *The Clinical Journal of Pain* 2015;**31**(6):557-63. [DOI: 10.1097/ajp.0000000000000171]

Mansfield 2016

Mansfield KE, Sim J, Jordan JL, Jordan KP. A systematic review and meta-analysis of the prevalence of chronic widespread pain in the general population. *Pain* 2016;**157**(1):55-64.

Mayer 2019

Mayer S, Spickschen J, Stein KV, Crevenna R, Dorner TE, Simon J. The societal costs of chronic pain and its determinants: the case of Austria. *PLoS One* 2019;**14**(3):e0213889.

McGuire 2017

McGuire BE, Henderson EM, McGrath PJ. Translating e-pain research into patient care. *Pain* 2017;**158**(2):190-3. [DOI: 10.1097/j.pain.0000000000000686]

Moher 2009

Moher D, Liberati A, Tetzlaff J, Altman DG, the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Medicine* 2009;**6**:e1000097. [DOI: 10.1136/bmj.b2535]

Page 2020

Page MJ, Higgins JP, Sterne JA. Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.

Portelli 2016

Portelli P, Eldred C. A quality review of smartphone applications for the management of pain. *British Journal of Pain* 2016;**10**(3):135-40. [DOI: 10.1177/2049463716638700]

Raja 2020

Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. *Pain* 2020;**161**(9):1976-82.

Reid 2011

Reid KJ, Harker J, Bala MM, Truyers C, Kellen E, Bekkering GE, et al. Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. *Current Medical Research and Opinion* 2011;**27**(2):449-62. [DOI: 10.1185/03007995.2010.545813]

Review Manager 2020 [Computer program]

The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan). Version Version 5.4.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2020.

Rosser 2011

Rosser BA, Eccleston C. Smartphone applications for pain management. *Journal of Telemedicine and Telecare* 2011;**17**(6):308-12. [DOI: 10.1258/jtt.2011.101102]

Schünemann 2013

Schünemann H, Brożek J, Guyatt G, Oxman A, editors. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html 2009;**6**:e1000097.

Scott 2007

Scott KM, Bruffaerts R, Tsang A, Ormel J, Alonso J, Angermeyer MC, et al. Depression–anxiety relationships with chronic physical conditions: results from the World Mental Health surveys. *Journal of Affective Disorders* 2007;**103**(1):113-20. [DOI: 10.1016/j.jad.2007.01.015]

Slattery 2019

Slattery BW, Haugh S, O'Connor L, Francis K, Dwyer CP, O'Higgins S, et al. An evaluation of the effectiveness of the modalities used to deliver electronic health interventions for chronic pain: systematic review with network meta-analysis. *Journal of Medical Internet Research* 2019;**21**(7):e11086. [DOI: 10.2196/11086]

Treede 2019

Treede RD, Rief W, Barke A, Qasim A, Bennett M, Benoliel R, et al. Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). *Pain* 2019;**160**(1):19-27.

Tsang 2008

Tsang A, Von Korff M, Lee S, Alonso J, Karam E, Angermeyer MC, et al. Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders. *The Journal of Pain* 2008;**9**(10):883-91. [DOI: 10.1016/j.jpain.2008.05.005]

Williams 2020

Williams AC, Fisher E, Hearn L, Eccleston C. Psychological therapies for the management of chronic pain (excluding headache) in adults. *Cochrane Database of Systematic Reviews* 2020, Issue 8. Art. No: CD007407. [DOI: 10.1002/14651858.CD007407.pub4]



Zilcha-Mano 2017

Zilcha-Mano S. Is the alliance really therapeutic? Revisiting this question in light of recent methodological advances. *American Psychologist* 2017;**72**(4):311-25. [DOI: 10.1037/a0040435]

References to other published versions of this review Eccleston 2014

Eccleston C, Fisher E, Craig L, Duggan G B, Rosser B A, Keogh E. Psychological therapies (Internet-delivered) for the management of chronic pain in adults. *Cochrane Database of Systematic Reviews* 2014, Issue 2. Art. No: CD010152. [DOI: 10.1002/14651858.CD010152.pub2]

APPENDICES

Appendix 1. Appendix 1: MEDLINE search strategy (OVID)

- 1. exp Pain/
- 2. Fibromyalgia/
- 3. (pain* or fibromyalgia* or neuralgia*).tw.
- 4.1 or 2 or 3
- 5. exp Internet/
- 6. (Internet or web or blog* or "social media" or online or www or email* or e-mail*).tw.
- 7. exp Telecommunications/
- 8. (telemedicine or tele-medicine).tw.
- 9. (telehealth or tele-health).tw.
- 10. (ehealth or e-health).tw.
- 11. (mobile health or mhealth or m-health).tw.
- 12. ICT.tw.
- 13. ((inform* or communicat* or interact*) adj6 (computer* or technolog* or software)).tw.
- 14. ((health* or treat* or therap* or intervention* or assist* or selfmanag* or self-manag*) adj6 (computer* or technolog* or software)).tw.
- 15. "world wide web".tw.
- 16. (telephone* or phone* or mobile* or cellphone* or apps or text* or SMS or smartphone*).tw.
- 17. (virtual reality or augmented reality or VR or AR).tw.
- 18. ("Interactive voice response" or IVR).tw.
- 19.5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 17 or 18
- 20. 4 and 19
- 21. randomized controlled trial.pt.
- 22. controlled clinical trial.pt.
- 23. randomized.ab.
- 24. placebo.ab.
- 25. drug therapy.fs.
- 26. randomly.ab.
- 27. trial.ab.
- 28. or/21-27
- 29. exp animals/ not humans.sh.
- 30. 28 not 29
- 31. 20 and 30
- 32. exp Child/ or exp Adolescent/ or exp infant/
- 33. 31 not 32
- 34. exp Psychotherapy/
- 35. exp PSYCHOLOGY/
- 36. ((behavio#r* adj therapy) or (behavio#r* adj therapies)).tw.
- 37. ((cognitive adj therapy) or (cognitive adj therapies)).tw.
- 38. mindfulness.tw.
- 39. meditat*.tw.
- 40. meditat*.tw.
- 41. psychotherap*.tw.
- 42. (psychological adj treatment*).tw.
- 43. ((psychological adj therapy) or (psychological adj therapies)).tw.
- 44. 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43
- 45. 33 and 44

HISTORY

Protocol first published: Issue 1, 2021



CONTRIBUTIONS OF AUTHORS

Ben Rosser will oversee the project and is responsible for updating the review.

Ben Rosser, Emma Fisher, Christopher Eccleston, Geoffrey Duggan, and Edmund Keogh contributed to the design and authoring of the protocol.

All authors will contribute to the enactment of the protocol, analysis, and authoring of the final review.

DECLARATIONS OF INTEREST

BR: None known.

EF: None known.

CE: None known. Since CE is an author as well as being a PaPaS Co-ordinating Editor during the development of this protocol, we acknowledge the input of Neil O'Connell who acted as Sign-off Editor for this review. CE had no input into the editorial decisions or processes for this review.

GD: None known; GD is a clinical psychologist and works with clients with chronic pain.

EK: None known.

SOURCES OF SUPPORT

Internal sources

· No sources of support supplied

External sources

· Versus Arthritis, UK

Dr Fisher is support by Career Development Award from Versus Arthritis

· National Institute for Health Research (NIHR), UK

Cochrane Infrastructure funding to the Cochrane Pain, Palliative and Supportive Care Review Group (PaPaS)